I've just heard a rumour Dom that Welby will be the new host of MOTD and Lineker is going to become the new Archbishop of Canterbury. If true then our non-exec board dodged a couple of bullets there imho. |
HST, I have questioned, as you know what do our corporate brokers do for us publicly. Broker notes, price targets, bringing in new partners. I'm only a novice, perhaps there is more paddling beneath the water but I can't see it. Director buys, it's been months since we speculated why no director buys, there cannot be sensitive information which prevents director buys months before and significant signed off deal (can there?). |
Because nobody has told Frank that OXB has shareholders? |
Repeated more times than UKGold I know, but I think the random walk with the daily chart doesn't ever really mean anything on low volume. Something of a trend happening over a few days on better than normal daily volume then fair enough, but at the moment OXB is very quiet.
In fact, for a company with a new broom CFO about to rehabilitate itself and start its first profitable year since 2021 and almost certainly its record ever sales year, then it's eerily quiet isn't it? Almost locked down quiet.
No broker notes. No Times interview with Frank following the results. If there has been any self-promotion of what we have / where we are going then I've missed it. The latest corporate presentation on the website is still the interims slides.
This "time of the year" or running silent for some other reason?
Best answer wins a signed copy of Prince Harry's memoire. Runner up receives 2 copies. |
Really funny to watch the britishbulls bot dealing system get in such a complete pickle this week over trading this share. Issued a sell order as price drifted back to 410, then needed to reverse it a day later when short sided so asked clients to move to cash and will no doubt move back to buy as share price drifts higher. LTBH can be somewhat less stressful (sometimes!).... |
 Its going to be full steam ahead for US equities and all things crypto for a few days at least.As for the UK,Reeves budget and the threat of tariffs suggest a relatively drab performance by UK equities.Of course its worth noting that if, perchance,you were interested in getting involved in crypto,the FCA have decided,along with the European Union,that its downright unhealthy for your average punter to have anything to do with crypto.So US crypto ETFs are off limits,for example,to your average uk investor as a convenient means of sharing in this prospective Trump/Musk inspired bonanza.You can buy crypto through an exchange like Coinbase but its not a simple affair and involves an element of security risk.Why half the globe is permitted to run wild sampling a universe of investment opportunities while the other half suffer a 1984 Big Brother syndrome is not quite clear.There are self assigned parties out there who appear to believe that they know best and we need protecting from ourselves.Sorry to ramble off topic,its an age thing. |
The Trump victory seems to be influencing the investors into favouring certain parts of the market atm (e.g. BTC, US small cap) and I wonder what influence this has on the UK mid cap world especially with the recent budget influences to work through.
This may mean a lot more patience in the interim - let's wait and see as they say :) |
Harry.....I've been quiet of late but I'm still here. Despite the threat of increased tariffs for goods manufactured in the U.K. or Europe, I still regard this share as being Trump neutral and thus far things appear to be developing nicely. Achieving sustainable profitability ASAP must be the key objective going forward: after that the general story should come more into play and plenty of influential people have eyes on here. Keep smiling Harry. |
I'm sure it's their own vector Phil and it seems to have done very little for Syncona this morning too. |
SJ,
Probably a little before your time but IJ used to be one of the bulls here. Frequent contributor, regularly taking part with the entertainment committee sweep entries and such. Then came the fall when the market turned on us and something changed. Maybe it's PTSD or similar, but I became the whipping boy at that point. I don't know what he wrote the other day because he was filtered long ago, but I can guess. I also know that there are a few others here who will vote up anything which pokes me in the eye for reasons which may or may not include OXB.
Do I care? Honestly no. Would I prefer it didn't happen? Of course, but this is life and the reality of characters when given the shield of anonymity.
I've mentioned before that I got into the habit of doing the acting thread morale officer role when things weren't so great for OXB and I've never really stopped. I don't do it with my other shares and though I intend to see OXB out now, it's not something I'll ever do again.
If along the way it's helped out a few people with things they might not have ordinarily found / known about whilst sat in isolation with some shares they were concerned about, then I'm happy with that and will call the whole thing good. |
Do we think that is one of our clients Cousin? |
Autolus have received their FDA approval for commercial launch |
Dearie,dearie,me.
Harry has never made any secret of his ‘love’ of OXB.It is very much his hobby and he will hold the stock through thick and thin.His rose tinted glasses in no way detract from his exemplary knowledge of the company and the biotech industry.I have never looked to these (or any other BB) to give other than a very opinionated and subjective guidance of where the share price is heading.What Harry provides is an extensive knowledge of OXB which are the tools to make an educated assessment of how the shares should be valued.Whether his investment in OXB has been successful (which i understand it has) is irrelevant really.In an increasingly fickle world,i find Harry’s loyalty to OXB more worthy of praise than caustic wit. |
icejelly, that's a bit harsh mate. |
Maybe you have me filtered (can't blame you, I filter a few myself) but Phil's probably noticed that I replied to your same point back in September and linked to it when on the same subject yesterday.
In many less words this time, I think if OXB were a biologics basher who recently decided to have a go at CGT but had no vectors of their own to offer then it would be a really good comparison.
As it stands, probably not.
Unless they are distressed in some way I would be surprised if any of our large long term holders (who sat through the '21 peak) were interested in 3x today. It would have to be a lot more than that imho. My long term hunch has been that Novo are just waiting for better future numbers so that a multiple acceptable to them comes up with the right figure for the people who matter. |
Thanks. I still can’t see it. I must only get access to some of the thread |
You didn’t look very hard Xoptimist, we’ve been talking about it all afternoon. |
Greetings everybody. I am sure many of you will have clocked that Avid Bioservices was bought this week by a couple of large specialist healthcare private equity funds including the UK’s GHO. I am guessing you will have discussed this but I cant see any posts. Perhaps this got lost in the US election results on Wednesday.
I know many of you shot me down last time when I suggested that Avid was one of our better CDMO comparables – albeit operating in a slightly different space in antibodies.
However close you think it is to being a comparable I think it is nevertheless worth noting that Avid was sold for $1.1bn (£851m) – a 22% premium to market - or 6.8 times multiple of their forward guidance for FY2025 sales of $160-164m –17% growth rate over FY2024 (about half compared to our current estimated 3 year CAGR of 35%).
If Avid is a decent industry comparable then OXB on similar multiples would be worth £884m today (or £8,35 a share). (I have used Frank’s 2024 revenue guidance as Avid is already halfway through their FY2025 but of course there would be a case for OXB being valued on its forward revenue estimate of £175m of revenue for 2025).
Avid is in the larger antibody market and therefore carries a lower risk profile than OXB but this market generally has lower margins; more competition and lower barriers to entry. On the other hand, Avid is narrowly profitable, which is obviously a valuation plus.
Whilst many of you will intelligently argue that OXB is unique with much superior competitive advantage and R&D depth and knowledge (creating some kind of a moat) – nevertheless I would happily take 6.8 times sales this year and next (£1,19bn on FY2025 sales of £175m or £11,23 a share).
And if OXB is really so unique and superior and deserves a higher multiple than Avid’s 6.8 then hallelujah to that!
Sadly, we are a long way away from these valuation levels with OXB currently trading with a market cap of about £440m ($568m) or about half the valuation the PE guys have put on Avid. And we are trading at 3.4 times our 2024 estimated revenue and 2.5 times 2025 est.
If Novo does emerge as a potential buyer at least the Avid deal might establish a minimum benchmark – although perhaps there are other PE firms that can see that taking OXB private could unlock much greater value. In any event hopefully soon we will start to close what is a clear valuation gap with increasing benchmarks and comparables. |
All evidence which we have seen Dom (basically the interims presentation) is that it's all going very well. GMP suite utilisation for 2025 is in excess of 80% which is very good and of course where we make most of our money. This at a time when some of our competitors are struggling.
I would hope that both France and Boston know what they are doing as both worked on, then produced viral vectors before. Only real difference short term is that Boston is now going to be selling LV into the US region directly and France will be doing the same into the EU.
I agree about integration burning up management time, but I think Frank has already thinned out the duplications.
It's always been my understanding that the cGMP regs are what they are and the scientists will do what they do - with massive QA/QC/Validation oversight, so none of that is likely to change, even if the management structure above them does.
My glass half full here at the moment is that our woes are simply that not enough people know our story because it's smallcap and so they haven't looked.
Some news where OXB can tag on "profitability next year on £180m+ turnover" and people will look.
At the moment though? Still the covid vaccine manufacturer who doesn't do that anymore. |
Of course there IS another alternative..... that there is nothing very much going on at the moment and progress is stalled?
After all, management changes, integration issues, finding synergies between 3 centres can all burn up time. |
Unfortunately we have seen this at the back end of the year before. If there is some catalyst (most likely news) then great and we may get some good movement on the back of it. No news and we're likely to go sideways.
I do think we are due something and have been in that position for a long time now (my logic of this posted previously a lot) but the only time I ever saw shortcuts in process and regulation was during covid. So if it's a regulator we are waiting for then that will take as long as it takes. If it's a commercial supply purchase order which we are waiting for then that will get signed when the partner is ready. There's nothing that we (or OXB) can do to change that.
440k volume a few days ago vs what seems to be very low volume today is curious but probably means nothing. We have to wait until close of course to see what the real number is for today (there could easily be a lot of delayed trades yet to be shown). |
Lots of tiny trades.... is that a lack of interest? |
News required to get over the line before Xmas then but FT250 inclusion in 2025 seems very probable.OXB remains,in my book,a very attractive purchase in the UK equity market which faces a potentially arduous 2025.Starmer and Reeves have performed a Lord and Lady Macbeth on private enterprise-'t'were well,it were done quickly'-and hit business with sizeable cost increases.A situation which could be exacerbated by Trump's moves on the tariff front.Consequentially,Reeves calculations as to tax take could well prove optimistic as profitability slides Around 70% of demand in the UK is consumer driven and the Labour budget could well compromise that demand as tax related costs eat into corporate margins.In this context,OXB would appear as a relatively attractive investment. |
Speakers
André Raposo, PhD, Director, Innovation Department, Oxford Biomedica
Gareth McCathie, PhD, Group Lead, Oxford Biomedica
Thomas Evans, Principal Scientist, Oxford Biomedica |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
